Thus, we first evaluated individually the performance of the candidate biomarkers, and AFP, which is a currently used diagnostic biomarker for HCC and used as a positive control, in serum of an independent HCC validation cohort (designated as serum validation cohort 1) for initial validation and biomarker selection. Here, AFP is linked to hepatocellular carcinoma.